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Objectives
To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in
HIV-infected patients initiating antiretroviral therapy in Cameroon.
Methods
Baseline blood samples from 169 patients were tested retrospectively for hepatitis B surface antigens
(HBsAg), anti-hepatitis B core (anti-HBc), anti-HCV and – if HBsAg or anti-HCV result was positive
or indeterminate – for HBV DNA or HCV RNA, respectively, using the Cobas Ampliprep/Cobas
TaqMan quantitative assay (Roche Diagnostics GmbH, Mannheim, Germany).
Results
HBV DNA was detected in 14 of the 18 patients with positive or indeterminate HBsAg results [8.3%
of the total study population, 95% conﬁdence interval (CI) 4.6–13.5]. The median HBV viral load was
2.47   10
7IU/mL [interquartile range (IQR) 3680–1.59   10
8; range 270 to 42.2   10
8]. Twenty-
one patients (12.4%, 95% CI 7.9–18.4) were found with HCV RNA (all with positive HCV serology).
The median HCV viral load was 928000IU/mL (IQR 178400–2.06   10
6; range 640–5.5   10
6).
No patient was co-infected with HBV and HCV. In multivariate analysis, HCV co-infection was
associated with greater age [ 45 years vs. o45 years, odds ratio (OR) 11.89, 95% CI 3.49–40.55,
Po0.001] and abnormal serum alanine aminotransferase level [ 1.25   upper limit of normal
(ULN) vs. o1.25   ULN, OR 7.81, 95% CI 1.54–39.66, P50.01]; HBV co-infection was associated
with abnormal serum aspartate aminotransferase level (OR 4.33, 95% CI 1.32–14.17, P50.02).
Conclusions
These high rates of active HBV and HCV co-infections in HIV-positive Cameroonian patients
requiring antiretroviral therapy underline the need to promote: (i) screening for HBVand HCV before
treatment initiation; (ii) accessibility to tenofovir (especially in HBV-endemic African countries);
and (iii) accessibility to treatment for HBV and HCV infections.
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Introduction
While HIV-related morbidity and mortality are decreasing
thanks to the scaling up of antiretroviral therapy in Africa,
co-infections with hepatitis B virus (HBV) or hepatitis C
virus (HCV) are catching the attention of medical doctors
and other health professionals because of the consequent
emerging impact of liver disease [1,2]. High seropreva-
lences of all three infections are found in Africa [1].
Unfortunately, the prevalence of active hepatitis B or C
co-infections (i.e. positive HBV DNA or HCV RNA) in
African patients requiring anti-HIV treatment has not been
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85documented extensively. A recent South African study
investigated HBV co-infection (but not HCV co-infection),
while a Nigerian study investigated HCV co-infection (but
not HBV co-infection) [3,4]. In contrast, we investigated the
presence of both HBV DNA and HCV RNA in HIV-infected
patients initiating antiretroviral therapy in Cameroon.
Patients and methods
Patients infected with HIV-1 initiated antiretroviral therapy
in 2001–2003 in two major hospitals in Yaounde ´ in the
context of two clinical research projects (109 and 60
patients, respectively) designed to assess antiretroviral
treatment. Methods and patients have been described in
detail elsewhere [5,6]. Brieﬂy, the eligibility criteria were:
age over 18 years; AIDS or a CD4 count below 350cells/mL;
a Karnofsky score over 50%; and no contraindications to
antiretroviral treatment, including serum liver enzyme
levels less than ﬁve times the upper limit of normal (ULN)
value in the ﬁrst project or less than three times the ULN
value in the second project.
Hepatitis B and C markers were assessed retrospectively
on baseline blood samples frozen at –80 1C. Enzyme
immunoassays (EIA) were used to detect hepatitis B surface
antigens (Monolisa Ag HBs Plus; Bio-Rad, Marnes la
Coquette, France) and antibodies to hepatitis B core
(Monolisa anti-HBc Plus; Bio-Rad). Plasma HBV DNA was
tested in positive or indeterminate hepatitis B surface
antigens (HBsAg) samples using the Cobas Ampliprep/
Cobas TaqMan quantitative assay (Roche Diagnostics
GmbH, Mannheim, Germany; quantiﬁcation range of 12–
2.2   10
8IU/mL). Screening for antibodies to hepatitis C
virus (anti-HCV) was performed using a third-generation
EIA (Ortho HCV EIA 3.0; Ortho-clinical Diagnostics,
Riratan, NJ, USA); positive or indeterminate samples were
conﬁrmed using a recombinant immunoblot assay (Chiron
RIBA HCV 3.0 SIA; Chiron Corporation, Emeryville, CA,
USA). HCV RNA was assessed using the Cobas Ampliprep/
Cobas TaqMan quantitative assay (Roche Diagnostics
GmbH; quantiﬁcation range of 15–6.9   10
7IU/mL) in
samples that were positive or indeterminate for at least one
screening test.
The Fisher’s exact test was used to compare the
distribution of qualitative variables between the infection
groups (HBV or HCV co-infected patients vs. HIV mono-
infected patients). For continuous variables, comparisons
were based on the non-parametric Mann–Whitney two-
sample test. Multivariate logistic regressions were used to
identify factors associated with HBV or HCV co-infection.
Analyses were performed using STATA 10.0 software
(STATA Corporation, College Station, TX, USA).
Results
Between January 2001 and April 2003, 169 HIV-1 infected
patients started antiretroviral therapy. Two-thirds of
patients were women (n5113). The median age was
35.0 years [interquartile range (IQR) 29.3–41.1]. Most
patients were symptomatic for HIV (42% were at Centers
for Disease Control and Prevention stage B and 44% were
at stage C). The median CD4 count was 135cells/mL( I Q R
67–218) and median HIV-1 viral load was 5.3log10 -
RNAcopies/mL (IQR 4.7–5.6). Patients received either
zidovudine, lamivudine and nevirapine (n585) or stavu-
dine, lamivudine and nevirapine (n584).
Seventeen patients (10.1%) had positive HBsAg results;
one other patient (0.6%) had an indeterminate result. In a
sub-set of 109 patients, antibodies to hepatitis B core
(anti-HBc) were found in 89 patients (81.7%) and three
other patients (2.8%) had indeterminate results. HBV DNA
was detected in 14 of the 18 patients with positive or
indeterminate HBsAg results [8.3% of the total study
population, 95% conﬁdence interval (CI) 4.6–13.5]. The
positive predictive value of HBsAg was 76.5% (13 of 17
patients). The median HBV viral load in the 14 patients
was 2.47   10
7IU/mL (IQR 3680–1.59   10
8;r a n g e2 7 0t o
42.2   10
8). The only patient with an indeterminate
HBsAg result was found to be positive for anti-HBc and
had an HBV viral load of 3680IU/mL.
Serology for HCV was positive in 28 patients (16.6%)
and indeterminate in four other patients (2.4%). Twenty-
one patients (12.4% of the total study population, 95% CI
7.9–18.4) were found with HCV RNA (all with positive
HCV serology). Therefore, the positive predictive value
of HCV serology was 75.0%. The median HCV viral
load was 928000IU/mL (IQR 178400–2.06   10
6;r a n g e
640–5.5   10
6). No patient was co-infected with HBV
and HCV.
Patients co-infected with HBV or HCV were comparable
in most characteristics to those infected with HIV alone
(Table 1). However, HCV co-infected patients were more
likely to be older and to have serum liver enzyme
elevations. HBV co-infected patients had signiﬁcant serum
aspartate aminotransferase (AST) elevations only. In multi-
variate analysis, HCV co-infection remained associated
with greater age [ 45 years vs. o45 years, odds ratio (OR)
11.89, 95% CI 3.49–40.55, Po0.001] and abnormal serum
alanine aminotransferase (ALT) level ( 1.25   ULN vs.
o1.25   ULN, OR 7.81, 95% CI 1.54–39.66, P50.01) but
not with abnormal serum AST level ( 1.25   ULN vs.
o1.25   ULN, OR 2.65, 95% CI 0.72–9.78, P50.14). After
adjustment for gender and serum ALT level, HBV co-
infection was associated with abnormal serum AST level
only (OR 4.33, 95% CI 1.32–14.17, P50.02).
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In this study, we found high rates of active HBV and HCV
co-infection in HIV-positive patients initiating antiretroviral
therapy in Cameroon (8.3 and 12.4%, respectively). Most of
these patients had high HBV or HCV viral load and
moderate serum liver enzyme elevations.
T h et r u ep r e v a l e n c eo fc o - i n f e c t i o n sc o u l de v e nb eh i g h e r
because seronegative blood samples were not tested for HBV
DNA or HCV RNA. Higher rates of negative HBsAg or anti-
HCV EIA results in viraemic samples have been observed in
immunocompromised HIV-infected patients [2,7]. In addition,
the exclusion of patients presenting with serum liver enzyme
levels higher than three or ﬁve times the ULN values
(depending on the initial study) could have led to an
underestimation of the prevalence. The comparison of our
HBV and HCV estimates to those reported by the few other
African studies in patients initiating antiretroviral therapy
should be viewed as indicative only because of the methodo-
logical differences. In South Africa, HBV DNA was detected in
40.6% of 192 patients (100% of 44 HBsAg-positive patients
and 23.0% of 148 HBsAg-negative patients) [3]. In Cameroon’s
neighbour Nigeria, 8.2% of 146 patients were found with HCV
RNA (all patients were tested for HCV viraemia) [4]. The
prevalence of co-infections in other HIV-infected populations
are much lower. For instance, HBV DNA was detected in 2.4%
of pregnant women in both Co ˆte d’Ivoire and South Africa
[8,9]. The prevalence of HCV RNA was 0% in blood donors in
Tanzania and 1.0% in pregnant women in Co ˆte d’Ivoire [8,10].
Table 1 Patient characteristics by infection group
HIV mono-infected
patients (n5134)
HBV co-infected
patients (n514) P-value*
HCV co-infected
patients (n521) P-value
w
Women (n) 91 (68%) 7 (50%) 0.2 15 (71%) 0.8
Age (years)
Median (IQR) 34.4 (28.4–39.7) 35.2 (32.2–41.1) 0.4 45.2 (37.6–52.5) o0.001
Classes (n) 0.8 o0.001
o35 73 (54%) 7 (50%) 5 (24%)
35–44 49 (37%) 5 (36%) 5 (24%)
45–54 12 (9%) 2 (14%) 8 (38%)
 55 0 0 3 (14%)
Body mass index (kg/m
2) [median (IQR)]
z 23.2 (21.6–24.7) 22.9 (21.3–24.2) 0.5 22.1 (20.1–25.7) 0.3
Karnofsky score (n) 0.4 0.4
o90% 20 (15%) 0 4 (19%)
90% 52 (39%) 6 (43%) 5 (24%)
100% 62 (46%) 8 (57%) 12 (57%)
CDC clinical stage (n) 0.9 0.7
A 19 (14%) 1 (7%) 3 (14%)
B 58 (43%) 6 (43%) 7 (33%)
C 57 (43%) 7 (50%) 11 (52%)
CD4 count (cells/mL)
Median (IQR) 138 (67–222) 113 (45–151) 0.4 150 (84–218) 0.9
Classes (n) 0.6 0.9
o50 23 (17%) 4 (29%) 3 (14%)
50–99 31 (23%) 2 (14%) 4 (19%)
100–199 39 (29%) 5 (36%) 7 (33%)
 200 41 (31%) 3 (21%) 7 (33%)
HIV-1 viral load (log10copies/mL)
§
Median (IQR) 5.3 (4.7–5.5) 5.1 (4.8–5.9) 0.5 5.3 (4.7–5.6) 0.8
Classes (n) 0.6 0.8
o4.0 14 (11%) 0 1 (5%)
4.0–4.9 38 (29%) 5 (36%) 6 (29%)
 5.0 81 (61%) 9 (64%) 14 (67%)
ALT level ( ULN)
Median (IQR) 0.6 (0.4–0.7) 0.7 (0.5–0.9) 0.2 0.9 (0.6–1.3) o0.001
 1.25 (n) 8 (6%) 1 (7%) 0.9 7 (33%) 0.001
AST level ( ULN)
z
Median (IQR) 0.8 (0.6–1.1) 1.1 (0.9–1.6) 0.03 1.4 (1.0–1.8) o0.001
 1.25 (n) 21 (17%) 6 (46%) 0.02 11 (55%) o0.001
*HBV co-infected patients vs. HIV mono-infected patients.
wHCV co-infected patients vs. HIV mono-infected patients.
zThree missing values.
§One missing value.
zNine missing values.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CDC, Centers for Disease Control; IQR, interquartile range; ULN, upper limit of normal.
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USA, where the prevalence of HIV, HBV and HCV in the
general population is lower than in Africa. However, the
predominant modes of transmission of all three infections
are similar in Western countries (intravenous drug use and
sexual contact) [11,12] whereas they appear very dissimilar
in Africa (for HIV, the heterosexual route; for HBV, close
contact within households during early childhood and, to a
lesser extent, vertical transmission; and for HCV, unclear
routes of transmission) [1,2].
Undetected HBV or HCV co-infections had clinical
implications for antiretroviral therapy in our patients. All
HBV co-infected patients received anti-HBV lamivudine
monotherapy, which has been shown to lead to frequent
emergence of drug resistance [13] and, consequently, to
possible acute hepatitis, fulminant hepatic failure and
death [2]. The World Health Organization now recommends
the use of tenofovir plus either lamivudine or emtricitabine
as the nucleoside reverse transcriptase inhibitor (NRTI)
backbone of antiretroviral therapy in HBV co-infected
patients whenever possible (tenofovir has been available in
Cameroon since 2007) [14]. Also, 46 and 55% of HBV and
HCV co-infected patients, respectively, received nevirapine
despite moderate liver enzyme elevations. In these patients,
efavirenz or a third NRTI is preferred [14].
Two strategies should be considered for the management
of HIV-infected patients needing treatment in Africa.
Where possible, testing for HBsAg and anti-HCV should
be performed systematically in addition to serum liver
enzymes before initiating antiretroviral therapy in order to
avoid nevirapine and anti-HBV lamivudine monotherapy
when necessary. Moreover, where possible (infrequent at
present in most African settings), HBV DNA and HCV RNA
should also be tested when hepatic infection is suspected in
order to identify patients with occult hepatitis B (negative
HBsAg and positive HBV DNA) or false negative anti-HCV
EIA results. Testing for HBV DNA would also limit the
inessential use of the costly tenofovir (23.5% of our
HBsAg-positive patients were not viraemic). If quantitative
assay can be performed, HBV DNA level (or HCV RNA level
if anti-HCV treatment is available) would serve to manage
antiviral therapy (initiation and response). Alternatively,
if testing of HBV and HCV is not feasible, ﬁrst-line
antiretroviral regimen in HBV-endemic African countries
should include tenofovir plus either lamivudine or
emtricitabine systematically. The combination of tenofovir,
emtricitabine and efavirenz, once a day, appears a very
good option. If nevirapine is prescribed, serum liver
enzymes should be monitored closely.
In conclusion, active HBV and HCV co-infections were
frequent in HIV-positive Cameroonian patients requiring
antiretroviral therapy. This ﬁnding underlines the need to
promote: (i) screening for HBV and HCV before treatment
initiation; (ii) accessibility to tenofovir (especially in HBV-
endemic African countries); and (iii) accessibility to treat-
ment for HBV and HCV infections (in addition to NRTIs).
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